FDA 2024: Watch For Trial-Diversity Guidance, Final Quality Systems Rewrite

 
• By Elizabeth Orr

Industry observers at RAPS Convergence in Montreal last week said the FDA’s agenda for 2024 is likely to include increased emphasis on MDUFA goals, enhanced cybersecurity requirements, the new QMSR, and more. 

People in business attire peep through binoculars behind the word 2024.
• Source: Shutterstock

More from Regulation

More from Conferences